Each milestone in Emcure’s journey embodies our steadfast commitment to innovation, quality, and patient well-being. These milestones are not just markers of progress but a testimony of our mission of delivering impactful healthcare solutions worldwide.
IPO Listing
Emcure’s IPO was successfully listed on Indian stock
exchanges, National Stock Exchange (NSE) and
Bombay Stock Exchange (BSE) on July 10, 2024.
Launch of Emcutix
Emcutix, a wholly owned subsidiary focused on
dermatology segment was launched in Oct 2024,
to provide breakthrough solutions in prescription,
consumer, and aesthetic dermatology.
Advancing Biopharmaceuticals
Expands R&D capabilities with
cutting-edge facilities focused on mRNA,
vaccines, and complex APIs.
Research Breakthroughs
Files 234 global patents, with 201 approved,
highlighting its R&D expertise in delivering
differentiated pharmaceutical solutions.
Award-Winning Formulations
Recognized for groundbreaking launches
such as Emluz and Orofer XT with multiple
accolades at the AWACS Awards.
Biologics Leadership
Becomes the domestic leader in three biologic therapies, reinforcing its commitment to
innovation in critical therapeutic areas.
Chiral Chemistry Leadership
Successfully develops and markets 11 chiral
molecules, setting benchmarks in drug efficacy and safety.
Global Expansion
Strengthens its global footprint by entering key international markets, extending its presence
to over 70 countries.
Pioneering Biologics
Introduces its first biologic product, marking a significant step in delivering
advanced treatment solutions.
API Manufacturing Excellence
Establishes its first Active Pharmaceutical Ingredient (API) manufacturing unit, laying the
foundation for a vertically integrated supply chain.
The Beginning
Emcure Pharmaceuticals is founded
with a vision to provide quality and affordable healthcare solutions globally.